A sound attenuating apparatus may include a replaceable sound attenuating device and an electronic receiver configured to mate with the replaceable sound attenuating device. The replaceable sound attenuating device may include a sound attenuating material having an embedded sensor element. The sensor element may have a property that corresponds to a type of replaceable sound attenuating device. The electronic receiver may detect the property of the sensor element. A computing device may determine the type of the replaceable sound attenuating device from the property of the sensor element and perform one or more operations based on the type of replaceable sound attenuating device, including audio control, safety warnings, personal attenuation rating determinations, and the like.

The present disclosure provides a system of gender specific pharmaceuticals. The system includes a first package of a pharmaceutical for use by a male and a second package of a pharmaceutical for use by a female. The first package includes a pharmaceutical for use by a male and a first label coupled to the first package, wherein at least one of the first package and first label includes a male specifier and a recommended male dosage. The second package includes a pharmaceutical for use by a female and a second label coupled to the second package, wherein at least one of the second package and second label includes a female specifier and a recommended female dosage.

A reconfigurable orthopedic implant trial comprising: (a) a first orthopedic component; (b) a second orthopedic component that includes a second sensor on a second articulating surface thereof, the second orthopedic component configured to removably mount to the first orthopedic component; (c) a third orthopedic component that includes a third sensor on a third articulating surface thereof, the third orthopedic component configured to removably mount to the first orthopedic component, where the second sensor and the third sensor are configured to generate kinematic data.

An implant delivery system can be configured to deliver an inflatable implant into a bladder via a urethra. The delivery system can comprise an elongate tubular body, an inflation tube and an implant decoupler. The tubular body can comprise a central lumen configured to hold an inflatable implant in an initial un-inflated state for delivery of the implant into the bladder. A method of use can include passing a distal tip of the elongate tubular body into the bladder. The implant can be inflated and released into the bladder.

A system for promoting medication adherence is provided. The system may receive medical information and medication access information via a medication adherence device, the medication adherence device having a housing configured to be removably coupled to a medicine container. The information may be used to form one or more blind spots which representative of symptoms of glaucoma and which may be produced on the display screen of a patient's client device. The system may use Gamblification and/or Gamification in which a blind spot obscures portions of a game of chance program and/or novelty game type program, respectively, from being observed on the display screen. As medical information and medication compliance information is received, the number, size, opacity, and/or shape of the blind spots produced on the display screen of a patient's client device may change to provide actual perception of visual loss which spurs patients to compliance.

A prosthesis system comprises plates that can be positioned against vertebrae and a selected resilient core that can be positioned between the plates to allow the plates to articulate. The selected resilient core can be chosen from a plurality of cores in response to patient characteristics, such as age and/or intervertebral mobility, such that the prosthesis implanted in the patient is tailored to the needs of the patient. The plurality of cores may comprise cores with different resiliencies, and one of the cores can be selected such that the upper and lower plates articulate with the desired shock absorbing resiliency and/or maximum angle of inclination when the one selected core is positioned between the plates.

A reconfigurable orthopedic implant trial comprising: (a) a first orthopedic component; (b) a second orthopedic component that includes a second sensor on a second articulating surface thereof, the second orthopedic component configured to removably mount to the first orthopedic component; (c) a third orthopedic component that includes a third sensor on a third articulating surface thereof, the third orthopedic component configured to removably mount to the first orthopedic component, where the second sensor and the third sensor are configured to generate kinematic data.

A prosthesis system comprises plates that can be positioned against vertebrae and a selected resilient core that can be positioned between the plates to allow the plates to articulate. The selected resilient core can be chosen from a plurality of cores in response to patient characteristics, such as age and/or intervertebral mobility, such that the prosthesis implanted in the patient is tailored to the needs of the patient. The plurality of cores may comprise cores with different resiliencies, and one of the cores can be selected such that the upper and lower plates articulate with the desired shock absorbing resiliency and/or maximum angle of inclination when the one selected core is positioned between the plates.

Medical implants comprising biocompatible materials and having surface features that may assist in biocompatibility upon implantation in the body are described. Methods for manufacturing such implants are also described. The manufacturing process may include applying a biocompatible material to a texturized surface of a mold. The implants may include various features to assist their positioning, fixation, and/or identification during and/or after implantation.

A method for implanting a prosthetic valve in a patient's body with minimum misalignment of commissures of the prosthetic valve to the commissures of a native aortic valve is disclosed. AoCA of a native aortic valve of a patient to be treated is determined and the prosthetic valve having three commissures is crimped on a delivery system having one or more aligners marked on its outer shaft. The aligners follow same axis. Crimping is done using a crimper and/or a confirmation gauge that includes one or more angle markings. Crimping is performed such that one of the commissures of the prosthetic valve is axially aligned with the AoCA identified on the angle markings on one of the crimper/confirmation gauge and at the same time, the one or more aligners face upwards. The crimped prosthetic valve is implanted by maintaining the aligner(s) pointing upward during the entire implantation procedure.